메뉴 건너뛰기




Volumn 55, Issue 3, 2016, Pages 397-405

Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic Malignancies

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) N (4 HYDROXYPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETAMIDE; ACETANILIDE DERIVATIVE; ANTINEOPLASTIC AGENT; BIRABRESIB; BRD2 PROTEIN, HUMAN; BRD3 PROTEIN, HUMAN; BRD4 PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; NUCLEAR PROTEIN; PROTEIN SERINE THREONINE KINASE; RNA BINDING PROTEIN; TRANSCRIPTION FACTOR;

EID: 84959145415     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0327-6     Document Type: Article
Times cited : (76)

References (20)
  • 1
    • 84867316537 scopus 로고    scopus 로고
    • BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
    • COI: 1:CAS:528:DC%2BC38XhsFaksLbP, PID: 22904298
    • Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52.
    • (2012) Blood. , vol.120 , pp. 2843-2852
    • Ott, C.J.1    Kopp, N.2    Bird, L.3    Paranal, R.M.4    Qi, J.5    Bowman, T.6
  • 2
    • 84865222098 scopus 로고    scopus 로고
    • Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition
    • COI: 1:CAS:528:DC%2BC38Xht1Wrs7jK, PID: 22645123
    • Zhang G, Liu R, Zhong Y, Plotnikov AN, Zhang W, Zeng L, et al. Down-regulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J Biol Chem. 2012;287:28840–51.
    • (2012) J Biol Chem. , vol.287 , pp. 28840-28851
    • Zhang, G.1    Liu, R.2    Zhong, Y.3    Plotnikov, A.N.4    Zhang, W.5    Zeng, L.6
  • 3
    • 84874720284 scopus 로고    scopus 로고
    • Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
    • Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). Oncotarget. 2012;1588–99.
    • (2012) Oncotarget , pp. 1588-1599
    • Herrmann, H.1    Blatt, K.2    Shi, J.3    Gleixner, K.V.4    Cerny-Reiterer, S.5    Müllauer, L.6
  • 4
    • 84877097843 scopus 로고    scopus 로고
    • Inhibition of BET bromodomain targets genetically diverse glioblastoma
    • COI: 1:CAS:528:DC%2BC3sXlsVCmsLo%3D, PID: 23403638
    • Cheng Z, Gong Y, Ma Y, Lu K, Lu X, Pierce LA, et al. Inhibition of BET bromodomain targets genetically diverse glioblastoma. Clin Cancer Res. 2013;19:1748–59.
    • (2013) Clin Cancer Res. , vol.19 , pp. 1748-1759
    • Cheng, Z.1    Gong, Y.2    Ma, Y.3    Lu, K.4    Lu, X.5    Pierce, L.A.6
  • 5
    • 84888106365 scopus 로고    scopus 로고
    • Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer
    • COI: 1:CAS:528:DC%2BC3sXhslyku7rF, PID: 24045185
    • Shimamura T, Chen Z, Soucheray M, Carretero J, Kikuchi E, Tchaicha JH, et al. Efficacy of BET bromodomain inhibition in KRAS-mutant non-small cell lung cancer. Clin Cancer Res. 2013;19:6183–92.
    • (2013) Clin Cancer Res. , vol.19 , pp. 6183-6192
    • Shimamura, T.1    Chen, Z.2    Soucheray, M.3    Carretero, J.4    Kikuchi, E.5    Tchaicha, J.H.6
  • 9
    • 85018175161 scopus 로고    scopus 로고
    • OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma (abstract no. 5531)
    • Todaro M, Boi M, Vurchio V, Ercole E, Machiorlatti R, Messana K, et al. OTX015, a novel BET inhibitor, is a promising anticancer agent for multiple myeloma (abstract no. 5531). Cancer Res. 2014;74:5531.
    • (2014) Cancer Res , vol.74 , pp. 5531
    • Todaro, M.1    Boi, M.2    Vurchio, V.3    Ercole, E.4    Machiorlatti, R.5    Messana, K.6
  • 10
    • 84925375324 scopus 로고    scopus 로고
    • The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs
    • COI: 1:CAS:528:DC%2BC2MXmtVahsbc%3D, PID: 25623213
    • Boi M, Gaudio E, Bonetti P, Kwee I, Bernasconi E, Tarantelli C, et al. The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs. Clin Cancer Res. 2015;21:1628–38.
    • (2015) Clin Cancer Res. , vol.21 , pp. 1628-1638
    • Boi, M.1    Gaudio, E.2    Bonetti, P.3    Kwee, I.4    Bernasconi, E.5    Tarantelli, C.6
  • 11
    • 0019487152 scopus 로고
    • History of pharmacokinetics
    • COI: 1:CAS:528:DyaL3MXktFOkt7w%3D, PID: 7025032
    • Wagner JG. History of pharmacokinetics. Pharmacol Ther. 1981;12:537–62.
    • (1981) Pharmacol Ther. , vol.12 , pp. 537-562
    • Wagner, J.G.1
  • 13
    • 84933040610 scopus 로고    scopus 로고
    • A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies
    • COI: 1:CAS:528:DC%2BC2cXhsVCrtbbO, PID: 25174395
    • Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A, et al. A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene. 2015;34:3357–68.
    • (2015) Oncogene , vol.34 , pp. 3357-3368
    • Althoff, K.1    Beckers, A.2    Bell, E.3    Nortmeyer, M.4    Thor, T.5    Sprussel, A.6
  • 14
    • 84908086741 scopus 로고    scopus 로고
    • Development and validation of an UPLC–MS/MS method for quantitative analysis of OTX015 in human plasma samples
    • COI: 1:CAS:528:DC%2BC2cXhslekt7vM
    • Odore E, Lokiec F, Weill S, Noel JK, Herait P, Bekradda M, et al. Development and validation of an UPLC–MS/MS method for quantitative analysis of OTX015 in human plasma samples. Anal Methods. 2014;6:9108–15.
    • (2014) Anal Methods. , vol.6 , pp. 9108-9115
    • Odore, E.1    Lokiec, F.2    Weill, S.3    Noel, J.K.4    Herait, P.5    Bekradda, M.6
  • 15
    • 19044400906 scopus 로고    scopus 로고
    • Maximum likelihood estimation in nonlinear mixed effects models
    • Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal. 2005;49:1020–38.
    • (2005) Comput Stat Data Anal. , vol.49 , pp. 1020-1038
    • Kuhn, E.1    Lavielle, M.2
  • 16
    • 0037115430 scopus 로고    scopus 로고
    • Model of chemotherapy-induced myelosuppression with parameter consistency across drugs
    • PID: 12488418
    • Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713–21.
    • (2002) J Clin Oncol. , vol.20 , pp. 4713-4721
    • Friberg, L.E.1    Henningsson, A.2    Maas, H.3    Nguyen, L.4    Karlsson, M.O.5
  • 18
    • 84959155506 scopus 로고    scopus 로고
    • Odore E, Rezai K, Riveiro E, Bourdel F, Herait P, Cvitkovic E, et al. A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies (abstract no. LB-231). Cancer Res. 2014;74:LB-231
    • Odore E, Rezai K, Riveiro E, Bourdel F, Herait P, Cvitkovic E, et al. A phase I pharmacokinetic study of OTX015 for the treatment of patients with hematologic malignancies (abstract no. LB-231). Cancer Res. 2014;74:LB-231.
  • 19
    • 84927645044 scopus 로고    scopus 로고
    • Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies (abstract no. 5LBA)
    • Stathis A, Quesnel B, Amorim S, Thieblemont C, Zucca E, Raffoux E, et al. Results of a first-in-man phase I trial assessing OTX015, an orally available BET-bromodomain (BRD) inhibitor, in advanced hematologic malignancies (abstract no. 5LBA). Eur J Cancer. 2014;50:196.
    • (2014) Eur J Cancer , vol.50 , pp. 196
    • Stathis, A.1    Quesnel, B.2    Amorim, S.3    Thieblemont, C.4    Zucca, E.5    Raffoux, E.6
  • 20
    • 84930699565 scopus 로고    scopus 로고
    • Pharmacokinetic/pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients
    • Chalret du Rieu Q, Fouliard S, White-Koning M, Kloos I, Chatelut E, Chenel M. Pharmacokinetic/pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients. Invest New Drugs. 2014;32:985–94.
    • (2014) Invest New Drugs , vol.32 , pp. 985-994
    • Chalret du Rieu, Q.1    Fouliard, S.2    White-Koning, M.3    Kloos, I.4    Chatelut, E.5    Chenel, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.